Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

P Saiag, R Gutzmer, P A Ascierto, M Maio, J-J Grob, P Murawa, B Dreno, M Ross, J Weber, A Hauschild, P Rutkowski, A Testori, E Levchenko, A Enk, L Misery, C Vanden Abeele, I Vojtek, O Peeters, V G Brichard, P Therasse, P Saiag, R Gutzmer, P A Ascierto, M Maio, J-J Grob, P Murawa, B Dreno, M Ross, J Weber, A Hauschild, P Rutkowski, A Testori, E Levchenko, A Enk, L Misery, C Vanden Abeele, I Vojtek, O Peeters, V G Brichard, P Therasse

Abstract

Background: Genomic profiling of tumor tissue may aid in identifying predictive or prognostic gene signatures (GS) in some cancers. Retrospective gene expression profiling of melanoma and non-small-cell lung cancer led to the characterization of a GS associated with clinical benefit, including improved overall survival (OS), following immunization with the MAGE-A3 immunotherapeutic. The goal of the present study was to prospectively evaluate the predictive value of the previously characterized GS.

Patients and methods: An open-label prospective phase II trial ('PREDICT') in patients with MAGE-A3-positive unresectable stage IIIB-C/IV-M1a melanoma.

Results: Of 123 subjects who received the MAGE-A3 immunotherapeutic, 71 (58.7%) displayed the predictive GS (GS+). The 1-year OS rate was 83.1%/83.3% in the GS+/GS- populations. The rate of progression-free survival at 12 months was 5.8%/4.1% in GS+/GS- patients. The median time-to-treatment failure was 2.7/2.4 months (GS+/GS-). There was one complete response (GS-) and two partial responses (GS+). The MAGE-A3 immunotherapeutic was similarly immunogenic in both populations and had a clinically acceptable safety profile.

Conclusion: Treatment of patients with MAGE-A3-positive unresectable stage IIIB-C/IV-M1a melanoma with the MAGE-A3 immunotherapeutic demonstrated an overall 1-year OS rate of 83.5%. GS- and GS+ patients had similar 1-year OS rates, indicating that in this study, GS was not predictive of outcome. Unexpectedly, the objective response rate was lower in this study than in other studies carried out in the same setting with the MAGE-A3 immunotherapeutic. Investigation of a GS to predict clinical benefit to adjuvant MAGE-A3 immunotherapeutic treatment is ongoing in another melanoma study.This study is registered at www.clinicatrials.gov NCT00942162.

Keywords: MAGE-A3 antigen; gene signature; immunotherapy; melanoma; predictive biomarkers.

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

Figures

Figure 1.
Figure 1.
Kaplan–Meier curve giving overall survival (OS) in the total treated population. pGS+, predictive gene signature-positive population; pGS−, predictive gene signature-negative population.
Figure 2.
Figure 2.
Kaplan–Meier curve giving progression-free survival (PFS) in the total treated population. pGS+, predictive gene signature-positive population; pGS−, predictive gene signature-negative population.

References

    1. Ulloa-Montoya F, Louahed J, Dizier B et al. . Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013; 31: 2388–2395.
    1. Balch CM, Gershenwald JE, Soong S-J et al. . Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199–6206.
    1. Eggermont AMM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014; 383: 816–827.
    1. Brasseur F, Rimoldi D, Liénard D et al. . Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995; 63: 375–380.
    1. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997; 9: 684–693.
    1. Kruit WHJ, van Ojik HH, Brichard VG et al. . Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005; 117: 596–604.
    1. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2010; 667: 111–123.
    1. Kruit WHJ, Suciu S, Dreno B et al. . Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized Phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in metastatic melanoma. J Clin Oncol 2013; 31: 2413–2420.
    1. Marchand M, Punt CJA, Aamdal S et al. . Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003; 39: 70–77.
    1. Vantomme V, Dantinne C, Amrani N et al. . Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 2004; 27: 124–135.
    1. Atanackovic D, Altorki NK, Stockert E et al. . Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004; 172: 3289–3296.
    1. Vansteenkiste J, Cho B, Vanakesa T et al. . MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC). Ann Oncol 2014; 25(25 Suppl 4): iv409–iv416.
    1. Therasse P, Arbuck SG, Eisenhauer EA et al. . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216.
    1. Boser B, Guyon I, Vapnik V. A training algorithm for optimal margin classifiers. In Fifth Annual Workshop on Computational Learning Theory ACM, Pittsburgh, 1992. pp. 144–152.
    1. Hodi FS, O'Day SJ, McDermott DF et al. . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.
    1. Burch PA, Croghan GA, Gastineau DA et al. . Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004; 60: 197–204.
    1. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013; 108: 479–485.
    1. Jamal-Hanjani M, Thanopoulou E, Peggs KS et al. . Tumour heterogeneity and immune-modulation. Curr Opin Pharmacol 2013; 13: 497–503.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe